Tech Company Financing Transactions
Aukera Therapeutics Funding Round
Aukera Therapeutics, operating out of Basel, secured $5.7 million from private investors, Kick Start Sales Force and Zürcher Kantonalbank.
Transaction Overview
Company Name
Announced On
12/11/2025
Transaction Type
Venture Equity
Amount
$5,700,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Spitalstrasse 41
Basel, 4056
Switzerland
Basel, 4056
Switzerland
Phone
Undisclosed
Website
Email Address
Overview
Aukera Therapeutics is a preclinical-stage biotech spin-off from the Biozentrum of the University of Basel. We develop the first RAPTOR inhibitors for the treatment of mTORC1-related pathologies. We combine mTOR expertise with an AI-driven drug discovery engine built for complex and hard-to-drug targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stefan Imseng
Browse more venture capital transactions:
Prev: 12/11/2025: Surf AI venture capital transaction
Next: 12/11/2025: LI.FI venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. All VC database entries reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs